NSAIDs modulate CDKN2A, TP53, and DNA content risk for progression to esophageal adenocarcinoma

PLoS Medicine

Volumn 4, Issue 2, 2007, Pages 0342-0353

  Galipeau, Patricia C ^a   Li, Xiaohong ^a   Blount, Patricia L ^a,b   Maley, Carlo C ^c   Sanchez, Carissa A ^a   Odze, Robert D ^d   Ayub, Kamran ^e   Rabinovitch, Peter S ^a,b   Vaughan, Thomas L ^a,b   Reid, Brian J ^a,b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c WISTAR INSTITUTE   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e VIRGINIA MASON MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLIN DEPENDENT KINASE INHIBITOR 2A; DNA; NONSTEROID ANTIINFLAMMATORY AGENT; PROTEIN P53; UNCLASSIFIED DRUG;

ADULT; AGED; ANEUPLOIDY; ARTICLE; BARRETT ESOPHAGUS; CANCER GROWTH; CANCER RISK; CONTROLLED STUDY; DRUG USE; ENDOSCOPIC BIOPSY; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS BIOPSY; FEMALE; FLOW CYTOMETRY; GENE MUTATION; HETEROZYGOSITY LOSS; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; RISK REDUCTION; TETRAPLOIDY; ADENOCARCINOMA; BIOPSY; CHROMOSOME 17; CHROMOSOME 9; DNA METHYLATION; ESOPHAGOSCOPY; ESOPHAGUS; ESOPHAGUS TUMOR; GENETICS; INCIDENCE; LONGITUDINAL STUDY; MIDDLE AGED; MUTATION; PATHOLOGY; PROSPECTIVE STUDY; RISK ASSESSMENT;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANEUPLOIDY; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BARRETT ESOPHAGUS; BIOPSY; CHROMOSOMES, HUMAN, PAIR 17; CHROMOSOMES, HUMAN, PAIR 9; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA; DNA METHYLATION; ESOPHAGEAL NEOPLASMS; ESOPHAGOSCOPY; ESOPHAGUS; FEMALE; HUMANS; INCIDENCE; LONGITUDINAL STUDIES; LOSS OF HETEROZYGOSITY; MALE; MIDDLE AGED; MUTATION; PROSPECTIVE STUDIES; RISK ASSESSMENT; TUMOR SUPPRESSOR PROTEIN P53;

EID: 33847617509     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.0040067     Document Type: Article

References (117)

1. O'Shaughnessy JA, Kelloff GJ, Gordon GB, Dannenberg AJ, Hong WK, et al. (2002) Treatment and prevention of intraepithelial neoplasia: An important target for accelerated new agent development. Clin Cancer Res 8: 314-346.
2. Kelloff GJ, O'Shaughnessy JA, Gordon GB, Hawk ET, Sigman CC (2003) Counterpoint: Because some surrogate end point biomarkers measure the neoplastic process they will have high utility in the development of cancer chemopreventive agents against sporadic cancers. Cancer Epidemiol Biomarkers Prev 12: 593-596.
3. Sullivan Pepe M, Etzioni R, Feng Z, Potter JD, Thompson ML, et al. (2001) Phases of biomarker development for early detection of cancer. J Natl Cancer Inst 93: 1054-1061.
4. Dannenberg AJ, Lippman SM, Mann JR, Subbaramaiah K, DuBois RN (2005) Cyclooxygenase-2 and epidermal growth factor receptor: Pharmacologic targets for chemoprevention. J Clin Oncol 23: 254-266.
5. King MC, Marks JH, Mandell JB (2003) Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 302: 643-646.
6. Hawk E, Lubet R, Limburg P (1999) Chemoprevention in hereditary colorectal cancer syndromes. Cancer 86: 2551-2563.
7. Grady WM (2003) Genetic testing for high-risk colon cancer patients. Gastroenterology 124: 1574-1594.
8. Jarvinen HJ, Aarnio M, Mustonen H, Aktan-Collan K, Aaltonen LA, et al. (2000) Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology 118: 829-834.
9. Giardiello FM, Yang VW, Hylind LM, Krush AJ, Petersen GM, et al. (2002) Primary chemoprevention of familial adenomatous polyposis with sulindac. N Engl J Med 346: 1054-1059.
10. Steinbach G, Lynch PM, Phillips RK, Wallace MH, Hawk E, et al. (2000) The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 342: 1946-1952.
11. Califano J, van der Riet P, Westra W, Nawroz H, Clayman G, et al. (1996) Genetic progression model for head and neck cancer: Implications for field cancerization. Cancer Res 56: 2488-2492.
12. Califano J, Westra WH, Meininger G, Corio R, Koch WM, et al. (2000) Genetic progression and clonal relationship of recurrent premalignant head and neck lesions. Clin Cancer Res 6: 347-352.
13. Lee JJ, Hong WK, Hittelman WN, Mao L, Lotan R, et al. (2000) Predicting cancer development in oral leukoplakia: Ten years of translational research. Clin Cancer Res 6: 1702-1710.
14. Rosin MP, Cheng X, Poh C, Lam WL, Huang Y, et al. (2000) Use of allelic loss to predict malignant risk for low-grade oral epithelial dysplasia. Clin Cancer Res 6: 357-362.
15. Mao L, Lee JS, Fan YH, Ro JY, Batsakis JG, et al. (1996) Frequent microsatellite alterations at chromosomes 9p21 and 3p14 in oral premalignant lesions and their value in cancer risk assessment. Nat Med 2: 682-685.
16. Hittelman WN, Kim HJ, Lee JS, Shin DM, Lippman SM, et al. (1996) Detection of chromosome instability of tissue fields at risk: In situ hybridization. J Cell Biochem 25: 57-62.
17. Bollschweiler E, Wolfgarten E, Gutschow C, Holscher AH (2001) Demographic variations in the rising incidence of esophageal adenocarcinoma in white males. Cancer 92: 549-555.
18. Vizcaino AP, Moreno V, Lambert R, Parkin DM (2002) Time trends incidence of both major histologic types of esophageal carcinomas in selected countries, 1973-1995. Int J Cancer 99: 860-868.
19. Brown LM, Devesa S (2002) Epidemiologic trends in esophageal and gastric cancer in the United States. Surg Oncol Clin North Am 11: 235-256.
20. Sampliner RE (2002) Updated guidelines for the diagnosis, surveillance, and therapy of Barrett's esophagus. Am J Gastroenterol 97: 1888-1895.
21. Bosetti C, Talamini R, Franceschi S, Negri E, Garavello W, et al. (2003) Aspirin use and cancers of the upper aerodigestive tract. Br J Cancer 88: 672-674.
22. Corley DA, Kerlikowske K, Verma R, Buffler P (2003) Protective association of aspirin/NSAIDs and esophageal cancer: A systematic review and meta-analysis. Gastroenterology 124: 47-56.
23. Gonzalez-Perez A, Garcia Rodriguez LA, Lopez-Ridaura R (2003) Effects of non-steroidal anti-inflammatory drugs on cancer sites other than the colon and rectum: A meta-analysis. BMC Cancer 3: 28.
24. Vaughan TL, Kristal AR, Blount PL, Levine DS, Galipeau PC, et al. (2002) NSAID use, BMI, and anthropometry in relation to genetic and cell cycle abnormalities in Barrett's Esophagus. Cancer Epidemiol Biomarkers Prev 11: 745-752.
25. Vaughan TL, Dong LM, Blount PL, Ayub K, Odze RD, et al. (2005) Nonsteroidal anti-inflammatory drugs and risk of neoplastic progression in Barrett's oesophagus: A prospective study. Lancet Oncol 6: 945-952.
26. Buttar NS, Wang KK, Leontovich O, Westcott JY, Pacifico RJ, et al. (2002) Chemoprevention of esophageal adenocarcinoma by COX-2 inhibitors in an animal model of Barrett's esophagus. Gastroenterology 122: 1101-1112.
27. Oyama K, Fujimura T, Ninomiya I, Miyashita T, Kinami S, et al. (2005) A COX-2 inhibitor prevents the esophageal inflammation-metaplasia-adenocarcinoma sequence in rats. Carcinogenesis 26: 565-570.
28. Barrett MT, Sanchez CA, Prevo LJ, Wong DJ, Galipeau PC, et al. (1999) Evolution of neoplastic cell lineages in Barrett oesophagus. Nat Genet 22: 106-109.
29. Jenkins GJ, Doak SH, Parry JM, D'Souza FR, Griffiths AP, et al. (2002) Genetic pathways involved in the progression of Barrett's metaplasia to adenocarcinoma. Br J Surg 89: 824-837.
30. Eads CA, Lord RV, Kurumboor SK, Wickramasinghe K, Skinner ML, et al. (2000) Fields of aberrant CpG island hypermethylation in Barrett's esophagus and associated adenocarcinoma. Cancer Res 60: 5021-5026.
31. Wong DJ, Paulson TG, Prevo LJ, Galipeau PC, Longton G, et al. (2001) p16 INK4a lesions are common, early abnormalities that undergo clonal expansion in Barrett's metaplastic epithelium. Cancer Res 61: 8284-8289.
32. Bian YS, Osterheld MC, Fontolliet C, Bosman FT, Benhattar J (2002) p16 inactivation by methylation of the CDKN2A promoter occurs early during neoplastic progression in Barrett's esophagus. Gastroenterology 122: 1113-1121.
33. Suspiro A, Pereira AD, Afonso A, Albuquerque C, Chaves P, et al. (2003) Losses of heterozygosity on chromosomes 9p and 17p are frequent events in Barrett's metaplasia not associated with dysplasia or adenocarcinoma. Am J Gastroenterol 98: 728-734.
34. Galipeau PC, Cowan DS, Sanchez CA, Barrett MT, Emond MJ, et al. (1996) 17p (p53) allelic losses, 4N (G2/tetraploid) populations, and progression to aneuploidy in Barrett's esophagus. Proc Natl Acad Sci U S A 93: 7081-7084.
35. Galipeau PC, Prevo LJ, Sanchez CA, Longton GM, Reid BJ (1999) Clonal expansion and loss of heterozygosity at chromosomes 9p and 17p in premalignant esophageal (Barrett's) tissue. J Natl Cancer Inst 91: 2087-2095.
36. Fennerty MB, Sampliner RE, Way D, Riddell R, Steinbronn K, et al. (1989) Discordance between flow cytometric abnormalities and dysplasia in Barrett's esophagus. Gastroenterology 97: 815-820.
37. Gimenez A, Minguela A, Parrilla P, Bermejo J, Perez D, et al. (1998) Flow cytometric DNA analysis and p53 protein expression show a good correlation with histologic findings in patients with Barrett's esophagus. Cancer 83: 641-651.
38. Meltzer SJ, Yin J, Huang Y, McDaniel TK, Newkirk C, et al. (1991) Reduction to homozygostiy involving p53 in esophageal cancers demonstrated by the polymerase chain reaction. Biochemistry 88: 4976-4980.
39. Tarmin L, Yin J, Zhou X, Suzuki H, Jiang HY, et al. (1994) Frequent loss of heterozygosity on chromosome 9 in adenocarcinoma and squamous cell carcinoma of the esophagus. Cancer Res 54: 6094-6096.
40. Menke-Pluymers MB, Mulder AH, Hop WC, van Blankenstein M, Tilanus HW (1994) Dysplasia and aneuploidy as markers of malignant degeneration in Barrett's oesophagus. The Rotterdam Oesophageal Tumour Study Group. Gut 35: 1348-1351.
41. Dolan K, Morris AI, Gosney JR, Field JK, Sutton R (2003) Loss of heterozygosity on chromosome 17p predicts neoplastic progression in Barrett's esophagus. J Gastroenterol Hepatol 18: 683-689.
42. Teodori L, Gohde W, Persiani M, Ferrario F, Tirindelli Danesi D, et al. (1998) DNA/protein flow cytometry as a predictive marker of malignancy in dysplasia-free Barrett's esophagus: Thirteen-year follow-up study on a cohort of patients. Cytometry 34: 257-263.
43. Reid BJ, Levine DS, Longton G, Blount PL, Rabinovitch PS (2000) Predictors of progression to cancer in Barrett's esophagus: Baseline histology and flow cytometry identify low- and high-risk patient subsets. Am J Gastroenterol 95: 1669-1676.
44. Reid BJ, Prevo LJ, Galipeau PC, Sanchez CA, Longton G, et al. (2001) Predictors of progression in Barrett's esophagus II: Baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression. Am J Gastroenterol 96: 2839-2848.
45. Rabinovitch PS, Longton G, Blount PL, Levine DS, Reid BJ (2001) Predictors of progression in Barrett's esophagus III: Baseline flow cytometric variables. Am J Gastroenterol 96: 3071-3083.
46. Reid B, Blount P, Rabinovitch P (2003) Biomarkers in Barrett's Esophagus. Gastrointestinal Clin North Am 13: 369-397.
47. Reid BJ, Blount PL, Feng Z, Levine DS (2000) Optimizing endoscopic biopsy detection of early cancers in Barrett's high-grade dysplasia. Am J Gastroenterol 95: 3089-3096.
48. Conio M, Cameron AJ, Romero Y, Branch CD, Schleck CD, et al. (2001) Secular trends in the epidemiology and outcome of Barrett's oesophagus in Olmsted County, Minnesota. Gut 48: 304-309.
49. Conio M, Blanchi S, Lapertosa G, Ferraris R, Sablich R, et al. (2003) Long-term endoscopic surveillance of patients with Barrett's esophagus. Incidence of dysplasia and adenocarcinoma: A prospective study. Am J Gastroenterol 98: 1931-1939.
50. Cameron AJ, Lomboy CT (1992) Barrett's esophagus: Age, prevalence, and extent of columnar epithelium. Gastroenterology 103: 1241-1245.
51. O'Connor JB, Falk GW, Richter JE (1999) The incidence of adenocarcinoma and dysplasia in Barrett's esophagus: Report on the Cleveland Clinic. Am J Gastroenterol 94: 2037-2042.
52. Haggitt RC (1994) Barrett's esophagus, dysplasia, and adenocarcinoma. Hum Pathol 25: 982-993.
53. Paulson TG, Galipeau PC, Reid BJ (1999) Loss of heterozygosity analysis using whole genome amplification, cell sorting, and fluorescence-based PCR. Genome Res 9: 482-491.
54. INK4a promoter is hypermethylated at a high frequency in esophageal adenocarcinomas. Cancer Res 57: 2619-2622.
55. Wong DJ, Foster SA, Galloway DA, Reid BJ (1999) Progressive region-specific de novo methylation of the p16 CpG island in primary human mammary epithelial cell strains during escape from M(0) growth arrest. Mol Cell Biol 19: 5642-5651.
56. Prevo LJ, Sanchez CA, Galipeau PC, Reid BJ (1999) p53-mutant clones and field effects in Barrett's esophagus. Cancer Res 59: 4784-4787.
57. Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate: A practical and powerful approach to multiple testing. J R Stat Soc (Ser B) 57: 289-300.
58. Farrow DC, Vaughan TL, Hansten PD, Stanford JL, Risch HA, et al. (1998) Use of aspirin and other nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer. Cancer Epidemiol Biomarkers Prev 7: 97-102.
59. Chow WH, Blot WJ, Vaughan TL, Risch HA, Gammon MD, et al. (1998) Body mass index and risk of adenocarcinomas of the esophagus and gastric cardia. J Natl Cancer Inst 90: 150-155.
60. Hampel H, Abraham NS, El-Serag HB (2005) Meta-analysis: Obesity and the risk for gastroesophageal reflux disease and its complications. Ann Intern Med 143: 199-211.
61. Lagergren J, Bergstrom R, Nyren O (1999a) Association between body mass and adenocarcinoma of the esophagus and gastric cardia. Ann Intern Med 130: 883-890.
62. Gammon MD, Schoenberg JB, Ahsan H, Risch HA, Vaughan TL, et al. (1997) Tobacco, alcohol, and socioeconomic status and adenocarcinomas of the esophagus and gastric cardia. J Natl Cancer Inst 89: 1277-1284.
63. Lindblad M, Rodriguez LA, Lagergren J (2005) Body mass, tobacco and alcohol and risk of esophageal, gastric cardia, and gastric non-cardia adenocarcinoma among men and women in a nested case-control study. Cancer Causes Control 16: 285-294.
64. Lagergren J, Bergstrom R, Lindgren A, Nyren O (2000) The role of tobacco, snuff and alcohol use in the aetiology of cancer of the oesophagus and gastric cardia. Int J Cancer 85: 340-346.
65. Wu A, Wan P, Bernstein L (2001) A multiethnic population-based study of smoking, alcohol and body size and risk of adenocarcinomas of the stomach and esophagus (United States). Cancer Causes Control 12: 721-732.
66. Wu AH, Tseng CC, Bernstein L (2003) Hiatal hernia, reflux symptoms, body size, and risk of esophageal and gastric adenocarcinoma. Cancer 98: 940-948.
67. Engel LS, Chow WH, Vaughan TL, Gammon MD, Risch HA, et al. (2003) Population attributable risks of esophageal and gastric cancers. J Natl Cancer 95: 1404-1413.
68. Bani-Hani K, Martin IG, Hardie LJ, Mapstone N, Briggs JA, et al. (2000) Prospective study of cyclin D1 overexpression in Barrett's esophagus: Association with increased risk of adenocarcinoma. J Natl Cancer Inst 92: 1316-1321.
69. Schulmann K, Sterian A, Berki A, Yin J, Sato F, et al. (2005) Inactivation of p16, RUNX3, and HPP1 occurs early in Barrett's-associated neoplastic progression and predicts progression risk. Oncogene 24: 4138-4148.
70. Murray L, Sedo A, Scott M, McManus D, Sloan JM, et al. (2006) TP53 and progression from Barrett's metaplasia to oesophageal adenocarcinoma in a UK population cohort. Gut 55: 1390-1397.
71. Sherr CJ (2004) Principles of tumor suppression. Cell 116: 235-246.
72. Sharpless NE (2005) INK4a/ARF: A multifunctional tumor suppressor locus. Mutat Res 576: 22-38.
73. Olivier M, Eeles R, Hollstein M, Khan MA, Harris CC, et al. (2002) The IARC TP53 database: New online mutation analysis and recommendations to users. Hum Mutat 19: 607-614.
74. Shackney SE, Shackney TV (1997) Common patterns of genetic evolution in human solid tumors. Cytometry 29: 1-27.
75. Ko LJ, Prives C (1996) p53: Puzzle and paradigm. Genes Dev 10: 1054-1072.
76. Maley CC, Reid BJ (2003) Barrett's esophagus as an example of the evolution of cell lineages in cancer. Encyclopedia of the Human Genome. London: Nature Publishing Group. 5,000 p.
77. Maley CC, Reid BJ (2005) Natural selection in neoplastic progression of Barrett's esophagus. Semin Cancer Biol 15: 474-483.
78. Maley CC, Galipeau PC, Li X, Sanchez CA, Paulson TG, et al. (2004) Selectively advantageous mutations and hitchhikers in neoplasms: p16 lesions are selected in Barrett's esophagus. Cancer Res 64: 3414-3427.
79. Maley CC, Galipeau PC, Li X, Sanchez CA, Paulson TG, et al. (2004) The combination of genetic instability and clonal expansion predicts progression to esophageal adenocarcinoma. Cancer Res 64: 7629-7633.
80. McManus DT, Olaru A, Meltzer SJ (2004) Biomarkers of esophageal adenocarcinoma and Barrett's esophagus. Cancer Res 64: 1561-1569.
81. Paulson TG, Reid BJ (2004) Focus on Barrett's esophagus and esophageal adenocarcinoma. Cancer Cell 6: 11-16.
82. van Lieshout EM, Jansen JB, Peters WH (1998) Biomarkers in Barrett's esophagus (review). Int J Oncol 13: 855-864.
83. Reid BJ (2001) p53 and neoplastic progression in Barrett's esophagus. Am J Gastroenterol 96: 1321-1323.
84. Weston AP, Banerjee SK, Sharma P, Tran TM, Richards R, et al. (2001) p53 protein overexpression in low grade dysplasia (LGD) in Barrett's esophagus: Immunohistochemical marker predictive of progression. Am J Gastroenterol 96: 1355-1362.
85. Fahmy M, Skacel M, Gramlich TL, Brainard JA, Rice TW, et al. (2004) Chromosomal gains and genomic loss of p53 and p16 genes in Barrett's esophagus detected by fluorescence in situ hybridization of cytology specimens. Mod Pathol 17: 588-596.
86. Wales MM, Biel MA, el Deiry W, Nelkin BD, Issa JP, et al. (1995) p53 activates expression of HIC-1, a new candidate tumour suppressor gene on 17p13.3. Nat Med 1: 570-577.
87. Zeini M, Traves PG, Lopez-Fontal R, Pantoja C, Matheu A, et al. (2006) Specific contribution of p19(ARF) to nitric oxide-dependent apoptosis. J Immunol 177: 3327-3336.
88. Maley CC, Galipeau PC, Finley JC, Wongsurawat VJ, Li X, et al. (2006) Genetic clonal diversity predicts progression to esophageal adenocarcinoma. Nat Genet 38: 468-473.
89. Giardiello FM, Hamilton SR, Krush AJ, Piantadosi S, Hylind LM, et al. (1993) Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 328: 1313-1316.
90. Nugent KP, Farmer KC, Spigelman AD, Williams CB, Phillips RK (1993) Randomized controlled trial of the effect of sulindac on duodenal and rectal polyposis and cell proliferation in patients with familial adenomatous polyposis. Br J Surg 80: 1618-1619.
91. Higuchi T, Iwama T, Yoshinaga K, Toyooka M, Taketo MM, et al. (2003) A randomized, double-blind, placebo-controlled trial of the effects of rofecoxib, a selective cyclooxygenase-2 inhibitor, on rectal polyps in familial adenomatous polyposis patients. Clin Cancer Res 9: 4756-4760.
92. Bostwick DG, Shan A, Qian J, Darson M, Maihle NJ, et al. (1998) Independent origin of multiple foci of prostatic intraepithelial neoplasia: Comparison with matched foci of prostate carcinoma. Cancer 83: 1995-2002.
93. Saric T, Brkanac Z, Troyer DA, Padalecki SS, Sarosdy M, et al. (1999) Genetic pattern of prostate cancer progression. Int J Cancer 81: 219-224.
94. Wada K (2002) p16 and p53 gene alterations and accumulations in the malignant evolution of intraductal papillary-mucinous tumors of the pancreas. J Hepatobiliary Pancreat Surg 9: 76-85.
95. Feitelson MA, Sun B, Satiroglu Tufan NL, Liu J, Pan J, et al. (2002) Genetic mechanisms of hepatocarcinogenesis. Oncogene 21: 2593-2604.
96. Lindforss U, Papadogiannakis N, Zetterquist H, Lindberg G, Olivecrona H (2003) Distribution of genetic variants in preneoplastic areas of colorectal tumours. Eur J Surg Oncol 29: 491-496.
97. Farabegoli F, Champeme MH, Bieche I, Santini D, Ceccarelli C, et al. (2002) Genetic pathways in the evolution of breast ductal carcinoma in situ. J Pathol 196: 280-286.
98. Euhus DM, Cler L, Shivapurkar N, Milchgrub S, Peters GN, et al. (2002) Loss of heterozygosity in benign breast epithelium in relation to breast cancer risk. J Natl Cancer Inst 94: 858-860.
99. Chow NH, Cairns P, Eisenberger CF, Schoenberg MP, Taylor DC, et al. (2000) Papillary urothelial hyperplasia is a clonal precursor to papillary transitional cell bladder cancer. Int J Cancer 89: 514-518.
100. Bulashevska S, Szakacs O, Brors B, Eils R, Kovacs G (2004) Pathways of urothelial cancer progression suggested by Bayesian network analysis of allelotyping data. Int J Cancer 110: 850-856.
101. Czerniak B, Li L, Chaturvedi V, Ro JY, Johnston DA, et al. (2000) Genetic modeling of human urinary bladder carcinogenesis. Genes Chromosomes Cancer 27: 392-402.
102. Gazdar AF, Bader S, Hung J, Kishimoto Y, Sekido Y, et al. (1994) Molecular genetic changes found in human lung cancer and its precursor lesions. Cold Spring Harb Symp Quant Biol 59: 565-572.
103. Boland CR, Sato J, Appelman HD, Bresalier RS, Feinberg AP (1995) Microallelotyping defines the sequence and tempo of allelic losses at tumour suppressor gene loci during colorectal cancer progression. Nat Med 1: 902-909.
104. Fearon ER, Vogelstein B (1990) A genetic model for colorectal tumorigenesis. Cell 61: 759-767.
105. Li M, Lotan R, Levin B, Tahara E, Lippman SM, et al. (2000) Aspirin induction of apoptosis in esophageal cancer: A potential for chemo-prevention. Cancer Epidemiol Biomarkers Prev 9: 545-549.
106. Souza RF, Shewmake K, Beer DG, Cryer B, Spechler SJ (2000) Selective inhibition of cyclooxygenase-2 suppresses growth and induces apoptosis in human esophageal adenocarcinoma cells. Cancer Res 60: 5767-5772.
107. Buttar NS, Wang KK, Anderson MA, Dierkhising RA, Pacifico RJ (2002) The effect of selective cyclooxygenase-2 inhibition in Barrett's esophagus epithelium: An in vitro study. J Natl Cancer Inst 94: 422-429.
108. Thun MJ, Henley SJ, Patrono C (2002) Nonsteroidal anti-inflammatory drugs as anticancer agents: Mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 94: 252-266.
109. Husain SS, Szabo IL, Tamawski AS (2002) NSAID inhibition of GI cancer growth: Clinical implications and molecular mechanisms of action. Am J Gastroenterol 97: 542-553.
110. Gupta RA, DuBois RN (2002) Cyclooxygenase-2 inhibitor therapy for the prevention of esophageal adenocarcinoma in Barrett's esophagus. J Natl Cancer Inst 94: 406-407.
111. Kaur BS, Khamnehei N, Iravani M, Namburu SS, Lin O, et al. (2002) Rofecoxib inhibits cyclooxygenase 2 expression and activity and reduces cell proliferation in BE. Gastroenterol 123: 60-67.
112. Baron JA, Cole BF, Sandler RS, Haile RW, Ahnen D, et al. (2003) A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 348: 891-899.
113. Sandler RS, Halabi S, Baron JA, Budinger S, Paskett E, et al. (2003) A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 348: 883-890.
114. Cook NR, Lee IM, Gaziano JM, Gordon D, Ridker PM, et al. (2005) Low-dose aspirin in the primary prevention of cancer: The Women's Health Study: A randomized controlled trial. JAMA 294: 47-55.
115. Anderson LA, Johnston BT, Watson RG, Murphy SJ, Ferguson HR, et al. (2006) Nonsteroidal anti-inflammatory drugs and the esophageal inflammation-metaplasia-adenocarcinoma sequence. Cancer Res 66: 4975-4982.
116. Sturmer T, Glynn RJ, Lee IM, Manson JE, Buring JE, et al. (1998) Aspirin use and colorectal cancer: Post-trial follow-up data from the Physicians' Health Study. Ann Intern Med 128: 713-720.
117. Sonnenberg A, Fennerty MB (2003) Medical decision analysis of chemoprevention against esophageal adenocarcinoma. Gastroenterology 124: 1758-1766.